Use of pine bark extract, at a dose of 200 milligrams per day, appears safe but did not improve risk factors for heart disease, according to a report in the September 27 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

“Although traditional strategies such as prescription medications, dietary changes and physical activity have proven benefits for reducing cardiovascular disease risk, a substantial population seeks alternative therapies, including various dietary supplements, to lower cardiovascular disease risk,” the authors write as background information in the article. Evidence supports the use of some supplements, including fish oil, for treating and preventing cardiovascular disease. However, evidence regarding safety and efficacy is lacking for other supplements marketed to reduce heart risks, including those containing flavonoids prevalent in extracts of pomegranate, grape seeds and pine bark. According to the authors, “pine bark may have possible cardiovascular benefits, especially for blood pressure.”

Rebecca L. Drieling, M.P.H., M.M.Q., of Stanford University School of Medicine, Stanford, Calif., and colleagues conducted a randomized, placebo-controlled, double-blind clinical trial of pine bark extract supplements. A total of 130 individuals at increased risk for cardiovascular disease were randomly assigned to take either 200 milligrams of pine bark extract or a placebo once per day for 12 weeks. Participants were asked not to lose weight, change their diet or begin taking any other medications or supplements during the study. Blood pressure and other risk factors were assessed at the beginning of the study and at six and 12 weeks.

Baseline risk factors for heart disease were the same in the pine bark and placebo groups. Over the course of the study, blood pressure decreased by 1 millimeter of mercury in patients taking pine bark and 1.9 millimeters of mercury in patients taking placebo. Other risk factors—including body mass index, blood cholesterol levels, liver enzyme test results, size of cholesterol particles and levels of insulin, lipoprotein(a), fasting blood glucose and the inflammatory marker C-reactive protein—also did not differ significantly between the two groups.

The researchers assessed blood pressure levels among subgroups of participants with higher risk for cardiovascular disease, and still found no differences between those who took pine bark and those who took placebo.

Although it is biologically plausible that pine bark extract could reduce blood pressure through its ability to relax blood vessels constricted by stress hormones epinephrine and norepinephrine, the extract tested in this study was safe but did not improve blood pressure or other heart disease risk factors, the authors note. “Although a different dosage or formulation might produce different results, our findings argue against recommending this pine bark extract to improve cardiovascular disease risk factors,” they conclude.

###

(Arch Intern Med. 2010;170[17]:1541-1547. Available pre-embargo to the media at http://www.jamamedia.org.)

Editor’s Note: This research was supported by a research grant from Toyo Shinyaku Co, Ltd, Saga, Japan. Toyo Shinyaku Co, Ltd provided study tablets (Toyo-FVG pine bark extract and placebo). Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.

###

Contact: Susan Ipaktchian
.(JavaScript must be enabled to view this email address)
650-725-5375
JAMA and Archives Journals